Relationship between azathioprine dosage and thiopurine metabolites in pediatric ibd patients: Identification of covariables using multilevel analysis

Therapeutic Drug Monitoring

Volumn 35, Issue 2, 2013, Pages 251-257

  Nguyen, Thi Van Anh ^a   Vu, Dinh H ^b   Nguyen, Thi Mai Hoang ^a   Lachaux, Alain ^c   Boulieu, Roselyne ^a,d  

^a Clinical and Therapeutic Aspects of the Skin Barrier Function   (France)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c HOSPICES CIVILS DE LYON   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

azathioprine dosage; inflammatory bowel disease; multilevel analysis; pediatric; thiopurine metabolites

Indexed keywords

6 METHYLTHIOINOSINE; ALANINE AMINOTRANSFERASE; AZATHIOPRINE; INFLIXIMAB; THIOGUANINE DERIVATIVE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; MULTILEVEL ANALYSIS; MULTIVARIATE ANALYSIS OF COVARIANCE; PRIORITY JOURNAL; SCHOOL CHILD;

6-MERCAPTOPURINE; ADOLESCENT; AGE FACTORS; AZATHIOPRINE; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GUANINE NUCLEOTIDES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; MULTILEVEL ANALYSIS; RETROSPECTIVE STUDIES; THIONUCLEOTIDES;

EID: 84875143574     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318282c3a6     Document Type: Article

References (44)

1. Griffiths AM, Hugot JP. Crohn disease. In: Walker WA, Goulet O, Kleinman RE, eds. Pediatric Gastrointestinal Disease. 4th ed. Hamilton, Canada: BC Decker; 2004: 789-824.
2. Leichtner AM, Higuchi L. Ulcerative colitis. In: Walker WA, Goulet O, Kleinman RE, eds. Pediatric Gastrointestinal Disease. Hamilton, Canada: BC Decker; 2004: 825-849.
3. van Asseldonk DP, Sanderson J, de Boer NKH, et al. Difficulties and possibilities with thiopurine therapy in inflammatory bowel disease-proceedings of the first thiopurine task force meeting. Dig Liver Dis. 2011; 43: 270-276.
4. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995; 123: 132-142.
5. Pearson DC, May GR, Fick G, et al. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev. 2000: CD000067.
6. Gearry RB, Barclay ML, Burt MJ, et al. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol Drug Saf. 2004; 13: 563-567.
7. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology. 2002; 122: 904-915.
8. Grossman AB, Noble AJ, Mamula P, et al. Increased dosing requirements for 6-mercaptopurine and azathioprine in inflammatory bowel disease patients six years and younger. Inflamm Bowel Dis. 2008; 14: 750-755.
9. Armstrong L, Sharif JA, Galloway P, et al. Evaluating the use of metabolite measurement in children receiving treatment with a thiopurine. Aliment Pharmacol Ther. 2011; 34: 1106-1114.
10. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 1992; 43: 329-339.
11. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980; 32: 651-662.
12. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest. 2003; 111: 1133-1145.
13. Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev. 2006; 58: 521-590.
14. Coulthard S, Hogarth L. The thiopurines: an update. Invest New Drugs. 2005; 23: 523-532.
15. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000; 118: 705-713.
16. Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut. 2001; 48: 642-646.
17. Ooi CY, Bohane TD, Lee D, et al. Thiopurine metabolite monitoring in paediatric inflammatory bowel disease. Aliment Pharmacol Ther. 2007; 25: 941-947.
18. Osterman MT, Kundu R, Lichtenstein GR, et al. Association of 6-Thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology. 2006; 130: 1047-1053.
19. Gearry RB, Barclay ML. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol. 2005; 20: 1149-1157.
20. Gibson PR, Gearry RB. Optimizing thiopurine therapy: more weight to the metabolite argument. J Gastroenterol Hepatol. 2010; 25: 1592-1594.
21. Derijks LJ, Gilissen LP, Engels LG, et al. Pharmacokinetics of 6-Mercap topurine in patients with inflammatory bowel disease: implications for therapy. Ther Drug Monit. 2004; 26: 311-318.
22. Stevens T, Achkar JP, Easley K, et al. Azathioprine formulation optimizes metabolite profile in inflammatory bowel disease. Aliment Pharmacol Ther. 2004; 20: 601-606.
23. Lowry PW, Franklin CL, Weaver AL, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut. 2001; 49: 665-670.
24. Hindorf U, Peterson C, Almer S. Assessment of thiopurine methyltransferase and metabolite formation during thiopurine therapy: results from a large Swedish patient population. Ther Drug Monit. 2004; 26: 673-678.
25. Ansari A, Arenas M, Greenfield SM, et al. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2008; 28: 973-983.
26. Hindorf U, Lindqvist M, Hildebrand H, et al. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2006; 24: 331-342.
27. Gilissen LP, Wong DR, Engels LG, et al. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy. J Crohns Colitis. 2012; 6: 698-707.
28. Balaiche J, Desager JP, Horsmans Y, et al. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease. Scand J Gastroenterol. 2001; 36: 71-76.
29. Achkar JP, Stevens T, Easley K, et al. Indicators of clinical response to treatment with six-mercaptopurine or azathioprine in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004; 10: 339-345.
30. Roblin X, Serre-Debeauvais F, Phelip JM, et al. Drug interaction between infliximab and azathioprine in patients with Crohn's disease. Aliment Pharmacol Ther. 2003; 18: 917-925.
31. Teichgräber U, Atreya I, Atreya R, et al. Infliximab treatment induces levels of the active azathioprine metabolite TGTP in Crohn's disease. Inflamm Bowel Dis. 2012.
32. Lilleyman JS, Lennard L, Rees CA, et al. Childhood lymphoblastic leukaemia: sex difference in 6-mercaptopurine utilization. Br J Cancer. 1984; 49: 703-707.
33. Bouhnik Y, Scemama G, Taï R, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet. 1996; 347: 215-219.
34. Van Der LR. Multilevel analysis of repeated measures data. Qual Quant. 1998; 32: 15-29.
35. Sandborn WJ, Tremaine WJ, Wolf DC, et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. Gastroenterology. 1999; 117: 527-535.
36. Pozler O, Chládek J, Malý J, et al. Steady-state of azathioprine during initiation treatment of pediatric inflammatory bowel disease. J Crohns Colitis. 2010; 4: 623-628.
37. Dervieux T, Boulieu R. Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. Clin Chem. 1998; 44: 551-555.
38. Boulieu R, Sauviat M, Dervieux T, et al. Phenotype determination of thiopurine methyltransferase in erythrocytes by HPLC. Clin Chem. 2001; 47: 956-958.
39. Bloomfeld RS, Bickston SJ, Levine ME, et al. Thiopurine methyltransferase activity is correlated with azathioprine metabolite levels in patients with inflammatory bowel disease in clinical gastroenterology practice. J Appl Res. 2006; 6: 282-287.
40. Gardiner SJ, Gearry RB, Burt MJ, et al. Allopurinol might improve response to azathioprine and 6-mercaptopurine by correcting an unfavorable metabolite ratio. J Gastroenterol Hepatol. 2011; 26: 49-54.
41. Sheffield LJ, Irving P, Gupta A, et al. Thiopurine methyltransferase and thiopurine metabolite testing in patients with inflammatory bowel disease who are taking thiopurine drugs. Pharmacogenomics. 2009; 10: 1091-1099.
42. Lilleyman JS, Lennard L. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet. 1994; 343: 1188-1190.
43. Gisbert J, Gomollón F, Cara C, et al. Thiopurine methyltransferase activity in Spain: a study of 14, 545 patients. Dig Dis Sci. 2007; 52: 1262-1269.
44. Loit E, Tricco AC, Tsouros S, et al. Pre-analytic and analytic sources of variations in thiopurine methyltransferase activity measurement in patients prescribed thiopurine-based drugs: a systematic review. Clin Biochem. 2011; 44: 751-757.